Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ribociclib
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-17 of 17 for your search:
Start Over
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011A2301, 2013-003084-61, NCT01958021
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011E2301, NCT02278120
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over, postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011F2301, NCT02422615
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMEK162X2114, NCT01781572
Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011X2106, NCT01857193
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011X2107, NCT01872260
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011X2108, NCT02088684
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011X2110C, NCT02292550
Phase Ib Dose-escalation, Phase II Study of LEE011 and Letrozole for Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011A2115C, NCT02333370
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CHDM201X2103C, NCT02343172
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLGX818X2109, NCT02159066
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011XUS03, NCT02187783
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011X2201, 2014-000428-12, NCT02300987
LEE011 in Neuroendocrine Tumors of Foregut Origin
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: 2014-0371, NCT02420691
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011X2101, 2009-017017-30, NCT01237236
CDK4/6 Inhibitor LEE011 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I 262914, NCI-2015-00280, P30CA016056, NCT02414724
Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL-ONCO 2015-01, NCT02429089
Start Over